Efficacy of etretinate (Tigason) in symptomatic oral lichen planus.
This study evaluated the maximum permitted dosage of etretinate (75 mg/day) as the first mode of systemic treatment of patients with symptomatic oral lichen planus. Six patients were treated and examined objectively and subjectively every 2 weeks for 2 months. At the end of the study 50% of patients reached an asymptomatic stage; improvement of clinical signs and symptoms was noted in all patients. However, on reevaluation 2 months after treatment was discontinued some clinical signs of recurrence were seen in all patients. Further follow-up for more than a year showed that the patients had reverted to the same frequency of recurrence as before the systemic use of etretinate.
Gorsky
M
M
Section of Oral Pathology and Oral Medicine, Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Israel.
Raviv
M
M
D000368:Aged; D005050:Etretinate / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008010:Lichen Planus / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
D005050:Etretinate